Citations

Clear

513 citation(s) found for "Ta, Casey".

e-Professionalism: A New Frontier in Medical Education
Kaczmarczyk, J, Chuang, Alice, Dugoff, Lorraine , Abbott, Jodi , Cullimore, Amie J., Dalrymple, John L. , Davis, Katrina, Hueppchen, Nancy A. , Katz, Nadine T. , Nuthalapaty, Francis S., Pradhan, Archana , Wolf, Abigail , Casey, Petra M.

Mayo Clinic

Teaching and Learning in Medicine | March 26, 2013 | Volume: 25 | Issue: 2 | Pages: 165-170

10.1080/10401334.2013.770741 | PMID 23530680 Get It

Acceleration apportionment: A method of improved 2D SENSE acceleration applied to 3D contrast‐enhanced MR angiography
Weavers, Paul T., Borisch, Eric A. , Johnson, Casey P. , Riederer, Stephen J.

Mayo Clinic

Magnetic Resonance in Medicine | March 1, 2013 | Volume: 71 | Issue: 2 | Pages: 672-680

10.1002/mrm.24700 | PMID 23450817 Get It

PurposeIn 2D SENSE‐accelerated 3D Cartesian acquisition, the net acceleration factor R is the product of the two individual accelerations, R = RY × RZ. Acceleration Apportionment tailors acceleration parameters (RY, RZ) to improve parallel imaging performance on a patient‐ and coil‐specific basis and is demonstrated in contrast‐enhanced MR angiography.MethodsA performance metric is defined based on coil sensitivity information which identifies the (RY, RZ) pair that optimally trades off image quality with scan time reduction on a patient‐specific basis. Acceleration Apportionment is evaluated using retrospective analysis of contrast‐enhanced MR angiography studies, and prospective studies in which optimally apportioned parameters are compared with standard acceleration parameters.ResultsThe retrospective studies show strong variability in optimal acceleration parameters between anatomic regions and between patients. Prospective application of apportionment to foot contrast‐enhanced MR angiography with an 8‐channel receiver array provides a 20% increase in net acceleration with improved contrast‐to‐noise ratio. Application to 16‐channel contrast‐enhanced MR angiography of the feet and calves suggests 10% acceleration increase to R > 13 and no contrast‐to‐noise ratio loss. The specific implementation allows the optimum (RY, RZ) pair to be determined within one minute.ConclusionOptimum 2D SENSE acceleration parameters can be automatically chosen on a per‐exam basis to allow improved performance without disrupting the clinical workflow. Magn Reson Med 71:672–680, 2014. © 2013 Wiley Periodicals, Inc.
Risk Factors for Development of Acute Kidney Injury in Critically Ill Patients: A Systematic Review and Meta-Analysis of Observational Studies
Cartin‐Ceba, Rodrigo , Kashiouris, Markos , Plataki, Maria , Kor, Daryl J. , Casey, Edward T., Gajic, Ognjen

Mayo Clinic

Critical Care Research and Practice | November 26, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-15

10.1155/2012/691013 | PMID 23227318 Get It

Background. Acute kidney injury (AKI) is a frequent complication of critically ill patients. The impact of different risk factors associated with this entity in the ICU setting is unknown.Objectives. The purpose of this research was to assess the risk factors associated with the development of AKI in critically ill patients by meta-analyses of observational studies.Data Extraction. Two reviewers independently and in duplicate used a standardized form to collect data from published reports. Authors were contacted for missing data. The Newcastle-Ottawa scale assessed study quality.Data Synthesis. Data from 31 diverse studies that enrolled 504,535 critically ill individuals from a wide variety of ICUs were included. Separate random-effects meta-analyses demonstrated a significantly increased risk of AKI with older age, diabetes, hypertension, higher baseline creatinine, heart failure, sepsis/systemic inflammatory response syndrome, use of nephrotoxic drugs, higher severity of disease scores, use of vasopressors/inotropes, high risk surgery, emergency surgery, use of intra-aortic balloon pump, and longer time in cardiopulmonary bypass pump.Conclusion. The best available evidence suggests an association of AKI with 13 different risk factors in subjects admitted to the ICU. Predictive models for identification of high risk individuals for developing AKI in all types of ICU are required.
Vasoconstrictor responsiveness during hyperbaric hyperoxia in contracting human muscle
Casey, Darren P. , Claus, Paul, Curry, Timothy B. , Joyner, Michael J.

Mayo Clinic

Journal of Applied Physiology | November 16, 2012 | Volume: 114 | Issue: 2 | Pages: 217-224

10.1152/japplphysiol.01197.2012 | PMID 23154993 Get It

Large increases in systemic oxygen content cause substantial reductions in exercising forearm blood flow (FBF) due to increased vascular resistance. We hypothesized that 1) functional sympatholysis (blunting of sympathetic α-adrenergic vasoconstriction) would be attenuated during hyperoxic exercise and 2) α-adrenergic blockade would limit vasoconstriction during hyperoxia and increase FBF to levels observed under normoxic conditions. Nine male subjects (age 28 ± 1 yr) performed forearm exercise (20% of maximum) under normoxic and hyperoxic conditions. Studies were performed in a hyperbaric chamber at 1 atmosphere absolute (ATA; sea level) while breathing 21% O2 and at 2.82 ATA while breathing 100% O2 (estimated change in arterial O2 content ∼6 ml O2/100 ml). FBF (ml/min) was measured using Doppler ultrasound. Forearm vascular conductance (FVC) was calculated from FBF and blood pressure (arterial catheter). Vasoconstrictor responsiveness was determined using intra-arterial tyramine. FBF and FVC were substantially lower during hyperoxic exercise than normoxic exercise (∼20–25%; P < 0.01). At rest, vasoconstriction to tyramine (% decrease from pretyramine values) did not differ between normoxia and hyperoxia ( P > 0.05). During exercise, vasoconstrictor responsiveness was slightly greater during hyperoxia than normoxia (−22 ± 3 vs. −17 ± 2%; P < 0.05). However, during α-adrenergic blockade, hyperoxic exercise FBF and FVC remained lower than during normoxia ( P < 0.01). Therefore, our data suggest that although the vasoconstrictor responsiveness during hyperoxic exercise was slightly greater, it likely does not explain the majority of the large reductions in FBF and FVC (∼20–25%) during hyperbaric hyperoxic exercise.
Influence of α-adrenergic vasoconstriction on the blunted skeletal muscle contraction-induced rapid vasodilation with aging
Casey, Darren P. , Joyner, Michael J.

Mayo Clinic

Journal of Applied Physiology | September 7, 2012 | Volume: 113 | Issue: 8 | Pages: 1201-1212

10.1152/japplphysiol.00734.2012 | PMID 22961267 Get It

We tested the hypothesis that elevated sympathetic tone is responsible for lower peak vasodilation after single muscle contractions in older adults. Young ( n = 13, 7 men and 6 women, age: 27 ± 1 yr) and older ( n = 13, 7 men and 6 women, age: 69 ± 2 yr) adults performed single forearm contractions at 10%, 20%, and 40% of maximum during 1) control, 2) sympathetic activation via lower body negative pressure (LBNP; −20 mmHg), and 3) intra-arterial infusion of phentolamine (α-adrenergic antagonist). Brachial artery diameter and velocities were measured via Doppler ultrasound, and forearm vascular conductance (FVC; in ml·min−1·100 mmHg−1) was calculated from blood flow (in ml/min) and blood pressure (in mmHg). Peak vasodilator responses [change in (Δ) FVC from baseline] were attenuated in older adults at 20% and 40% of maximum ( P < 0.05). LBNP reduced peak ΔFVC at 10% (98 ± 17 vs. 70 ± 12 ml·min−1·100 mmHg−1), 20% (144 ± 12 vs. 98 ± 3 ml·min−1·100 mmHg−1), and 40% (209 ± 20 vs. 161 ± 21 ml·min−1·100 mmHg−1, P < 0.01 vs. control) in younger adults but not in older adults (71 ± 11 vs. 68 ± 11, 107 ± 13 vs. 106 ± 16, and 161 ± 22 vs. 144 ± 22 ml·min−1·100 mmHg−1, respectively, P = 0.22–0.99). With phentolamine, peak ΔFVC was enhanced in older adults at each contraction intensity (100 ± 14, 147 ± 22, and 200 ± 26 ml·min−1·100 mmHg−1, respectively, P < 0.01 vs. control) but not in younger adults (94 ± 13, 153 ± 13, and 224 ± 27 ml·min−1·100 mmHg−1, respectively, P = 0.30–0.81 vs. control). Our data indicate that α-adrenergic vasoconstriction and/or blunted functional sympatholysis might contribute to the age-related decreases in skeletal muscle contraction-induced rapid vasodilation in humans.
α-Adrenergic Vasoconstriction Contributes to the Age-Related Increase in Conduit Artery Retrograde and Oscillatory Shear
Casey, Darren P. , Padilla, Jaume , Joyner, Michael J. , Padilla, Jaume

Mayo Clinic

Hypertension | September 5, 2012 | Volume: 60 | Issue: 4 | Pages: 1016-1022

10.1161/hypertensionaha.112.200618 | PMID 22949528 Get It

Aging is associated with increased retrograde and oscillatory shear in peripheral conduit arteries of humans. Although the mechanisms responsible for these age-related changes are not completely understood, augmented downstream α-adrenergic tone likely plays a significant role in this phenomenon. Therefore, in protocol 1, brachial artery diameter and blood velocity were measured via Doppler ultrasound during (1) rest (control), (2) endogenous norepinephrine release via intra-arterial infusions of tyramine, and (3) α-adrenergic blockade via infusions of phentolamine in young healthy humans (n=12). Tyramine increased brachial artery retrograde (−4.0±1.4 to −9.5±1.4 s –1 ) and oscillatory shear (0.05±0.02 to 0.18±0.05 arbitrary units), whereas phentolamine abolished retrograde and oscillatory shear ( P <0.05). Additionally, in protocol 2, we examined brachial artery shear patterns in young (n=12; 29±2 years) and older (n=13; 69±2 years) healthy adults during (1) rest (control), (2) sympathetic activation via lower body negative pressure, and (3) infusion of phentolamine. At rest, older adults exhibited greater brachial artery retrograde and oscillatory shear (−9.9±2.7 s –1 and 0.11±0.03 arbitrary units, respectively) compared with younger adults (−3.1±1.0 s –1 and 0.05±0.02 arbitrary units, respectively; P <0.05 for both). Lower body negative pressure increased retrograde and oscillatory shear in young ( P <0.05), but not older adults ( P =0.85–0.97), such that differences between young and older were eliminated ( P >0.05). During infusion of phentolamine, retrograde and oscillatory shear were abolished in young adults ( P <0.05) and markedly reduced, yet still persistent, in older adults ( P <0.01). Our data indicate that α-adrenergic vasoconstriction is a major contributor to age-related discrepancies in conduit artery shear-rate patterns at rest.
Buildup of image quality in view‐shared time‐resolved 3D CE‐MRA
Johnson, Casey P. , Polley, Thomas W., Glockner, James F., Young, Phillip M. , Riederer, Stephen J.

Mayo Clinic

Magnetic Resonance in Medicine | August 30, 2012 | Volume: 70 | Issue: 2 | Pages: 348-357

10.1002/mrm.24466 | PMID 22936574 Get It

Time‐resolved three‐dimensional contrast‐enhanced MR angiography often relies on view sharing of peripheral k‐space data to enable acquisition of angiograms with both high spatial resolution and a rapid frame rate. It is typically assumed that k‐space will be fully sampled during passage of the contrast bolus arterial phase. However, this is not the case when view sharing is incomplete, for example, at the leading edge of an enhancing vessel or if acquisition time is limited as in fluoroscopic tracking for multistation bolus chase MR angiography. Incomplete view sharing will degrade image quality, for example, by reducing vessel signal and sharpness and increasing undersampling artifacts. In this work, the evolution of angiogram quality with view sharing is quantitatively assessed in phantom experiments and in vivo contrast‐enhanced MR angiography calf studies. It is demonstrated that there are multiple sets of sequence parameters that can yield a target image update time, but the choice of parameters can profoundly affect how image quality evolves with view sharing. A fundamental tradeoff between vessel signal and sharpness and its relationship to the sequence temporal footprint is investigated and discussed. Magn Reson Med 70:348–357, 2013. © 2012 Wiley Periodicals, Inc.
Abstract LB-214: Interim results from a randomized Phase 1-2 first-in-human (FIH) study of PK/PD guided escalating doses of SGI-110, a novel subcutaneous (SQ) second generation hypomethylating agent (HMA) in relapsed/refractory MDS and AML
Rizzieri, David A. , Faderl, Stefan, Yee, Karen , Choy, Gavin, Oganesian, Aram , Taverna, Pietro, Azab, Mohammad , Issa, Jean‐Pierre J. , Roboz, Gail J. , O'Connell, Casey Lee , Stock, Wendy , Tibes, Raoul , Griffiths, Elizabeth A. , Chung, Woonbok , Kantarjian, Hagop M.

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: LB-214-LB-214

10.1158/1538-7445.am2012-lb-214 Get It

Abstract SGI-110 is a novel second generation HMA, formulated as a low volume SQ injection. It is designed as a dinucleotide incorporating decitabine and guanosine, to prolong in vivo exposure and potentially improve efficacy of its active component, decitabine by protecting decitabine from rapid deamination by cytidine deaminase. Preclinically, SGI-110 demonstrated potent activity in-vivo using different routes of administration. A randomized Phase 1-2 FIH PK/PD-guided, dose-escalation study is being conducted in subjects with relapsed/refractory intermediate or high-risk MDS or AML. The objective of the first stage of the study is to determine the safety and tolerability of SGI-110 and to establish the MTD and the biologically effective dose (BED). Subjects are randomized to one of two SQ regimens (daily x5 or once weekly x3, both given in 28-day courses). PD is evaluated by LINE-1 global DNA hypomethylation. The second stage of the study will be a randomized Phase 2 dose expansion, once the BED and MTD have been determined. Currently, 5 dose-cohorts have been fully enrolled, (n= 55) at doses ranging from 3mg/m2 to 60 mg/m2 daily x5, and 6mg/m2 to 90 mg/m2 weekly x3 but are not yet fully evaluable. PK guidance has allowed rapid dose escalation, and PD assessment of global hypomethylation has been correlated with increased dose and exposure levels. Apart from manageable local injection site pain, SGI-110 has been well tolerated. Other AE's were neutropenia, thrombocytopenia, or anemia. There have been 3 remissions in relapsed AML subjects: 1 CR with weekly (60mg/m2) and 1 PR and 1 CR with daily (36 and 60 mg/m2 respectively). The PK profile showed efficient conversion of SGI-110 to decitabine achieving exposures in the therapeutic range as predicted from the SGI-110 rational design, characterized by decitabine AUC in therapeutic range (cohorts 4-5), lower Cmax, and longer effective half life, as compared to historical data based on molar equivalent doses of IV decitabine. Dose-dependent hypomethylation induction in the first 5 cohorts was observed. The subject who achieved a CR had the highest degree of hypomethylation induction of all subjects tested to date, and also the highest decitabine AUC in the cohort. Updated efficacy, safety, PK, and PD data of both regimens will be presented. SGI-110 is safe and well tolerated to date; biologically effective and therapeutic dose levels have been achieved with little toxicity so far with both regimens. Preliminary efficacy (PR+CR) has been observed in relapsed AML subjects. The PK profile showed efficient conversion of SGI-110 to decitabine with achievable therapeutic exposures, longer apparent half life, and lower Cmax than predicted equivalent decitabine doses given IV. Global Hypomethylating effects were observed at all dose levels, evaluated to date with both regimens. The results justify the progress of the study to the second dose-expansion Phase 2 stage after establishing the BED and MTD. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-214. doi:1538-7445.AM2012-LB-214
Abstract 2930: Novel colorectal cancer loci in multiplex-proficient mismatch repair families
Cunningham, Julie M. , Cicek, Mine , Brooke, Fridley, Serie, Daniel, Diergaarde, Brenda , Kontriris, Theodore, Younghusband, Ban, Gallinger, Steven, Jenkins, Mark A. , Templeton, Allyson , Green, Roger, Parry, Susan, Young, Joanne , Thomas, Duncan C. , Lindor, Noralane M. , Thibodeau, Stephen N. , Goode, Ellen L. , CFR., Colon, Bamlet, William R. , Haile, Robert W. , Marchand, Loı̈c Le , Newcomb, Polly A. , Hopper, John L. , Casey, Graham , Schumacher, Fredrick R. , Chen, Zhu , Winship, Ingrid , Macrae, Finlay , Young, Graeme P. , Buchanan, Daniel D. , Bishop, D. Timothy , Potter, John D. , CFR., Colon, Jenkins, Mark A , Diergaarde, Brenda

Mayo Clinic

Cancer Research | August 13, 2012 | Volume: 72 | Issue: 8_Supplement | Pages: 2930-2930

10.1158/1538-7445.am2012-2930 Get It

Abstract A substantial proportion of familial colorectal cancer (CRC) is not a consequence of known susceptibility loci, such as mismatch repair (MMR) genes, supporting the existence of additional loci. To identify novel CRC loci, we conducted a genome-wide linkage scan in 356 white families with no evidence of defective MMR (i.e., no tumors with loss of expression of MMR proteins; no microsatellite instability (MSI)-high tumors, and no evidence of linkage to MMR genes). This represents the largest linkage analysis of proficient MMR (pMMR) familial CRC to date. Families were ascertained via the NCI-supported Colon Cancer Family Registry multi-site (Colon CFR) consortium, the City of Hope, and Memorial University of Newfoundland. A total of 1,612 individuals (average 5.0 per family, range 2-10 with an average of 2.2 affected and 2.8 unaffected individuals) were genotyped using genome-wide single nucleotide polymorphism linkage arrays; parametric and non-parametric linkage analysis used MERLIN in a priori-defined family groups. Five lod scores greater than 3.0 were observed, accounting for heterogeneity, in four chromosomal regions. The greatest lod scores were at 4q21.1 among families with mean age of diagnosis less than 50 years (dominant HLOD=4.51, α=0.84, 145.40 cM, rs10518142) and at 12q24.32 among all families (dominant HLOD=3.60, α=0.48, 285.15 cM, rs952093). Among families with four or more affected individuals and among clinic-based families, a common peak was observed at 15q22.31 (101.40 cM, rs1477798; dominant HLOD=3.07, α=0.29; dominant HLOD=3.03, α=0.32, respectively). Analysis of families with only two affected individuals yielded a peak at 8q13.2 (recessive HLOD=3.02, α=0.51, 132.52 cM, rs1319036). These linkage regions comprise previously unreported loci, supporting the hypothesis that novel loci contribute to CRC in familial pMMR cases. These loci are also largely distinct from those identified in case-control GWAS. To follow up on these findings, a custom Agilent Sure Select Target Enrichment panel has been designed for genes in three of these regions, in order to sequence probands using an Illumina HiSeq 2000. This study demonstrates the utility of family-based data and provides evidence for additional alleles for familial CRC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2930. doi:1538-7445.AM2012-2930